Difference between revisions of "Part:BBa K2549005:Design"
Line 7: | Line 7: | ||
===Design Notes=== | ===Design Notes=== | ||
− | + | The heavy-chain variable region (αCD19a) and light-chain variable region (αCD19b) were fused together using a glycine-rich peptide linker(3 repeats of GGGGS, or G4S)<ref>Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med, 2016 Mar;374(10):998 PMID: 26962747; DOI: 10.1056/NEJMx160005</ref>. | |
===Source=== | ===Source=== | ||
Line 13: | Line 13: | ||
===References=== | ===References=== | ||
− | |||
− | |||
− |
Revision as of 05:24, 7 October 2018
anti-CD19
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI site found at 444
Design Notes
The heavy-chain variable region (αCD19a) and light-chain variable region (αCD19b) were fused together using a glycine-rich peptide linker(3 repeats of GGGGS, or G4S)[1].
Source
from IDT(gBlock), codon optimized for human
References
- ↑ Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med, 2016 Mar;374(10):998 PMID: 26962747; DOI: 10.1056/NEJMx160005